이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Orthocell 대차 대조표 상태

재무 상태 기준 확인 6/6

Orthocell 의 총 주주 지분은 A$2.2M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$24.9M 및 A$22.7M 입니다.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	n/a
현금	AU$19.62m
주식	AU$2.18m
총 부채	AU$22.74m
총 자산	AU$24.92m

최근 재무 상태 업데이트

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Recent updates

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Nov 16

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Jul 29

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Mar 23

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

Dec 08

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

재무 상태 분석

단기부채: OCC 의 단기 자산 ( A$21.7M )이 단기 부채( A$4.7M ).

장기 부채: OCC 의 단기 자산( A$21.7M )이 장기 부채( A$18.0M ).

부채 대 자본 내역 및 분석

부채 수준: OCC 부채가 없습니다.

부채 감소: OCC 지난 5년간 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: OCC 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: OCC 무료 현금 흐름이 역사적 비율인 29.1 로 계속 증가할 경우 2.3 년 동안 충분한 현금 활주로를 보유하고 있습니다. 29.1 % 매년.

Orthocell 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기